CO033 | THE BURDEN OF CEREBRAL SMALL VESSEL DISEASE AND GLOBAL CORTICAL ATROPHY IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING REMISSION
Abstract
Background and aims. Immune-mediated thrombotic thrombocytopenic purpura (iTTP) can lead to long-term sequelae related to acute microvascular brain injury. Cerebral small vessel disease (cSVD) reflects chronic small vessel dysfunction and is a risk factor for stroke and cognitive decline. Global cortical atrophy (GCA) is a diffuse cortical brain loss reflecting neurodegeneration and/or vascular injury. Both are detectable on brain magnetic resonance (MRI). Data on the prevalence of cSVD and GCA in iTTP survivors are limited. To assess the prevalence of cSVD and GCA in iTTP patients during clinical remission. Methods. Fifty-seven iTTP patients underwent a brain MRI at least 12 months after the last acute episode. The cSVD burden was scored (0–4) based on lacunes, cerebral microbleeds (CMB), white-matter hyperintensities (WMH), and enlarged perivascular spaces (EPVS). GCA was graded 0 to 3 using the Pasquier scale. Associations between iTTP and cSVD/GCA were evaluated using binary and ordinal logistic regression with age adjustment. The associations of cSVD/GCA with cardiovascular risk factors, iTTP history, and ADAMTS13 activity were also explored. Results. ITTP patients had a median age of 57 years, with hypertension as the most prevalent cardiovascular risk factor (Table 1). cSVD was detected in 49% of iTTP patients vs 27% of controls, and there was a moderate burden (score ≥ 2) in 19% vs none. In iTTP, the most frequent lesions were CMB, WMH, and lacunes. cSVD scores were higher in iTTP vs. controls (ordinal OR 3.04, 95% CI 1.11-8.36), after age adjustment: OR 2.90, 95% CI 0.93-9.02. In analyses restricted to non-hypertensive participants, the case-control difference was less pronounced. GCA was significantly higher in iTTP than controls (age-adjusted logistic regression OR 12.27, 95% CI 2.07–72.89; ordinal logistic regression OR 15.87, 95% CI 2.60–96.72). cSVD and GCA were not significantly associated with other cardiovascular risk factors, time from first event, neurological symptoms at iTTP onset, number of relapses, or time with ADAMTS13 activity below 50%. Conclusions. ITTP patients during remission showed an increased prevalence of cSVD and GCA, and hypertension may contribute to the cSVD burden. Optimizing modifiable risk factors may mitigate long-term neurological sequelae.
Related
- CO031 | PREEMPTIVE RITUXIMAB IN ADAMTS13 RELAPSE DURING CLINICAL REMISSION OF IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A MULTICENTER ITALIAN STUDY
- CO036 | NEUROCOGNITIVE ASSESSMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS USING A COMPREHENSIVE TEST BATTERY IN A CROSS-SECTIONAL MRI-INTEGRATED STUDY
- PO063 | EVALUATION OF PLATELET ACTIVATION MARKERS IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA
- Murine Typhus Masquerading as Thrombotic Thrombocytopenic Purpura in a Patient With Newly Diagnosed HIV
- Genetic architecture of immune-mediated thrombotic thrombocytopenic purpura in Han Chinese individuals
BibTeX
@article{truma2026co033,
title = {{CO033 | THE BURDEN OF CEREBRAL SMALL VESSEL DISEASE AND GLOBAL CORTICAL ATROPHY IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING REMISSION}},
author = {Addolorata Truma},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/735},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO033 | THE BURDEN OF CEREBRAL SMALL VESSEL DISEASE AND GLOBAL CORTICAL ATROPHY IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING REMISSION
AU - Addolorata Truma
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/735
AB - Background and aims. Immune-mediated thrombotic thrombocytopenic purpura (iTTP) can lead to long-term sequelae related to acute microvascular brain injury. Cerebral small vessel disease (cSVD) reflects chronic small vessel dysfunction and is a risk factor for stroke and cognitive decline. Global cortical atrophy (GCA) is a diffuse cortical brain loss reflecting neurodegeneration and/or vascular injury. Both are detectable on brain magnetic resonance (MRI). Data on the prevalence of cSVD and GCA in iTTP survivors are limited. To assess the prevalence of cSVD and GCA in iTTP patients during clinical remission. Methods. Fifty-seven iTTP patients underwent a brain MRI at least 12 months after the last acute episode. The cSVD burden was scored (0–4) based on lacunes, cerebral microbleeds (CMB), white-matter hyperintensities (WMH), and enlarged perivascular spaces (EPVS). GCA was graded 0 to 3 using the Pasquier scale. Associations between iTTP and cSVD/GCA were evaluated using binary and ordinal logistic regression with age adjustment. The associations of cSVD/GCA with cardiovascular risk factors, iTTP history, and ADAMTS13 activity were also explored. Results. ITTP patients had a median age of 57 years, with hypertension as the most prevalent cardiovascular risk factor (Table 1). cSVD was detected in 49% of iTTP patients vs 27% of controls, and there was a moderate burden (score ≥ 2) in 19% vs none. In iTTP, the most frequent lesions were CMB, WMH, and lacunes. cSVD scores were higher in iTTP vs. controls (ordinal OR 3.04, 95% CI 1.11-8.36), after age adjustment: OR 2.90, 95% CI 0.93-9.02. In analyses restricted to non-hypertensive participants, the case-control difference was less pronounced. GCA was significantly higher in iTTP than controls (age-adjusted logistic regression OR 12.27, 95% CI 2.07–72.89; ordinal logistic regression OR 15.87, 95% CI 2.60–96.72). cSVD and GCA were not significantly associated with other cardiovascular risk factors, time from first event, neurological symptoms at iTTP onset, number of relapses, or time with ADAMTS13 activity below 50%. Conclusions. ITTP patients during remission showed an increased prevalence of cSVD and GCA, and hypertension may contribute to the cSVD burden. Optimizing modifiable risk factors may mitigate long-term neurological sequelae.
SN - 2785-5309
ER -